1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA's New Website May Facilitate Broader Outside Use Of Data

 
• By Derrick Gingery

Redesigned FDA.gov is expected to allow application programming interfaces, which could allow other software to talk to the site and potentially use its data.

New and old view of FDA website
FDA redesigned its website to appear better on mobile devices, in part because more than half of site visits originate from them.

The US Food and Drug Administration's redesigned website eventually may allow easier use of its data by outside groups, as well as improve the user experience.

The new FDA.gov, which launched on 26 April, has a more modern user interface that will improve accessibility no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Kennedy Maintains mRNA Negativity Even When Couched As Trump Success

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary's Sept. 4 appearance at the Senate Finance Committee also revealed more Republicans are souring on his vaccine policies, although most still support him.

US FDA Compounding Advisory Panel Hit Hardest By Recent Purges

 
• By Sarah Karlin-Smith

A Pink Sheet review found 10 FDA advisory panel members recently pulled off committees despite having time left in their appointed terms.

Offit’s VRBPAC Departure Raises Questions About Another HHS Panel Revamp

 
• By Sarah Karlin-Smith and Derrick Gingery

Offit, an outspoken critic of the Trump Administration's vaccine agenda, is no longer slated to serve two more years on the FDA's Vaccines and Related Biologics Products Advisory Committee.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

More from Agency Leadership

Brazil & Mexico Bet On Regulatory Reliance To Improve Pharmacovigilance & Access To Medicines

 
• By Francesca Bruce

Two of Latin America’s biggest regulators have signed a memorandum of understanding to deepen cooperation and improve access to medicines.

New US FDA AI Councils Will Focus On Internal, External Policy

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

EMA Learns Hard Lessons From US-Inspired Streamlining Pilot

 
• By Vibha Sharma

The European Medicines Agency’s ongoing pilot to streamline drug reviews by allowing companies to voluntarily pre-fill factual data in assessment report templates appears to add significant workload for industry, without delivering clear value to regulators.